CRS Clinical Research Services, part of the hVIVO Group, delivers end-to-end clinical pharmacology trial solutions with a focus on early-phase development and therapeutic specialisation. CRS’ capabilities span a broad range of indications, drug classes, and study designs, ensuring scientific excellence and operational reliability from First-in-Human (FIH) studies through Phase III trials.
CRS Clinical Research Services conducts Phase I trials in healthy volunteers and special populations across therapeutic areas including immunology, oncology, and infectious diseases. Experience includes work with small molecules, biologics, mRNA, siRNA, vaccines, and biosimilars.
CRS has extensive expertise in managing complex First-in-Human studies, including combination protocols that integrate single and multiple ascending dose (SAD/MAD) components, food effect assessments, and early patient cohorts within a single, cohesive trial design. This proven approach enables precise navigation of the unique challenges of early-phase development.
Additional services include bioavailability and bioequivalence studies, drug–drug and food interaction trials, biosimilar evaluations, and thorough QT/QTc assessments. Studies involving medical devices and trials in special populations—such as elderly participants, women-specific cohorts, and patients with renal or hepatic impairment—are conducted across CRS’ clinical trial sites.
CRS delivers Phase II–III trials with a strong therapeutic focus and access to well-characterised patient populations:
The CRS Mannheim site specialises in studies involving diabetes, obesity, MAFLD, MASH, arteriosclerosis, dyslipidaemia, and hypertension.
These services are delivered by CRS Berlin, a preferred partner to the hVIVO Group. CRS Berlin has expertise in women’s health trials covering endometriosis, PCOS, uterine fibroids, hormonal contraception, postmenopausal health, heavy menstrual bleeding, infertility, and sexual dysfunction, as well as dermatology studies in psoriasis, atopic dermatitis, rosacea, urticaria, acne, and pollinosis. Collaboration with dermatologists and access to an extensive patient base position CRS Berlin to expand into additional indications as new opportunities arise.
Vaccine trials are conducted through all CRS trial sites, supported by dedicated infrastructure and substantial experience in both prophylactic and therapeutic vaccine development.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
